Search Results - "Granier, Muriel"

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results by Verstovsek, Srdan, Passamonti, Francesco, Rambaldi, Alessandro, Barosi, Giovanni, Rumi, Elisa, Gattoni, Elisabetta, Pieri, Lisa, Zhen, Huiling, Granier, Muriel, Assad, Albert, Cazzola, Mario, Kantarjian, Hagop M., Barbui, Tiziano, Vannucchi, Alessandro M.

Get full text

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) by Matloub, Yousif, Gore, Lia, Loh, Mignon L., Pui, Chin-Hon, Hanley, Michael J., Lu, Vickie, Leonard, E. Jane, Granier, Muriel, Biondi, Andrea, Silverman, Lewis B.

“…Introduction: Ph+ ALL accounts for 3-5% of pediatric ALL and is associated with improved outcomes when tyrosine kinase inhibitors (TKIs) are added to…”
Get full text

ALL-049 A Phase 1/2 Study to Evaluate Ponatinib With Chemotherapy in Pediatric Patients With Relapsed/Resistant/Intolerant Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia or With T315I Mutation by Gore, Lia, Loh, Mignon, Pui, Ching-Hon, Matloub, Yousif, Hanley, Michael J., Du, Jichang, Hennessy, Meliessa, Granier, Muriel, Biondi, Andrea, Silverman, Lewis

Get full text

Poster: ALL-049 A Phase 1/2 Study to Evaluate Ponatinib With Chemotherapy in Pediatric Patients With Relapsed/Resistant/Intolerant Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia or With T315I Mutation by Gore, Lia, Loh, Mignon, Pui, Ching-Hon, Matloub, Yousif, Hanley, Michael J., Du, Jichang, Hennessy, Meliessa, Granier, Muriel, Biondi, Andrea, Silverman, Lewis

Get full text

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia by Martinelli, Giovanni, Papayannidis, Cristina, Piciocchi, Alfonso, Robustelli, Valentina, Soverini, Simona, Terragna, Carolina, Marconi, Giovanni, Lemoli, Roberto M., Guolo, Fabio, Fornaro, Antonella, Lunghi, Monia, de Fabritiis, Paolo, Candoni, Anna, Selleri, Carmine, Simonetti, Federico, Bocchia, Monica, Vitale, Antonella, Frison, Luca, Tedeschi, Alessandra, Cuneo, Antonio, Bonifacio, Massimiliano, Martelli, Maria Paola, D'Ardia, Stefano, Trappolini, Silvia, Tosi, Patrizia, Galieni, Piero, Fabbiano, Francesco, Abbenante, Maria Chiara, Granier, Muriel, Zhu, Zhaoyin, Wang, Mingyue, Sartor, Chiara, Paolini, Stefania, Cavo, Michele, Foà, Robin, Fazi, Paola, Vignetti, Marco, Baccarani, Michele

“…Tyrosine kinase inhibitors have improved survival for patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). However,…”
Get full text

ALL-167: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Relapsed, Resistant, or Intolerant Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) or Have the T315I Mutation by Gore, Lia, Loh, Mignon, Pui, Ching-Hon, Hanley, Michael J., Du, Jichang, Matloub, Yousif, Hennessy, Meliessa, Granier, Muriel, Biondi, Andrea, Silverman, Lewis

“…Ph+ ALL is associated with improved outcomes when tyrosine kinase inhibitors (TKIs) are added to chemotherapy, with 5-year event-free survival (EFS) and…”
Get full text

Poster: ALL-167: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Relapsed, Resistant, or Intolerant Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) or Have the T315I Mutation by Gore, Lia, Loh, Mignon, Pui, Ching-Hon, Hanley, Michael J., Du, Jichang, Matloub, Yousif, Hennessy, Meliessa, Granier, Muriel, Biondi, Andrea, Silverman, Lewis

Get full text

Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study by Evrard, Diane, Dumont, Clément, Gatineau, Michel, Delord, Jean-Pierre, Fayette, Jérôme, Dreyer, Chantal, Tijeras-Raballand, Annemilaï, de Gramont, Armand, Delattre, Jean-François, Granier, Muriel, Aissat, Nasredine, Garcia-Larnicol, Marie-Line, Slimane, Khemaies, Chibaudel, Benoist, Raymond, Eric, Le Tourneau, Christophe, Faivre, Sandrine

“…Mammalian target of rapamycin (mTOR) regulates cellular functions by integrating intracellular signals and signals from the tumor microenvironment (TME). The…”
Get full text

BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC by Bouattour, Mohamed, Fartoux, Laetitia, Rosmorduc, Olivier, Scatton, Olivier, Vibert, Eric, Costentin, Charlotte, Soubrane, Olivier, Ronot, Maxime, Granier, Muriel Magali, De Gramont, Armand, Belghiti, Jacques, Paradis, Valerie, Wendum, Dominique, Tijeras-Raballand, Annemilai, Hadengue, Alexandra, Brusquant, David, Chibaudel, Benoist, Raymond, Eric, Faivre, Sandrine J.

“…Abstract only 252 Background: This open-label, multicenter, phase II study aimed at investigating the activity of sorafenib including radiological,…”
Get full text

CAPRA: Safety, efficacy, and translational biomarkers of weekly everolimus, carboplatin, and paclitaxel as induction therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) by Raymond, Eric, Le Tourneau, Christophe, Gatineau, Michel, Delord, Jean-Pierre, Fayette, Jérôme, Dreyer, Chantal, Tijeras-Raballand, Annemilai, Albert, Sebastien, Granier, Muriel, Chibaudel, Benoist, Hadengue, Alexandra, Aissat, Nasredine, Slimane, Khemaies, Faivre, Sandrine J.

“…Abstract only 6036 Background: ThePI3K/mTOR pathway is activated in >50% of HNSCC with preclinical synergism between everolimus and carboplatin/paclitaxel…”
Get full text